Thyroid Eye Disease: Multidisciplinary Management of Treatment-Associated Hyperglycemia (Online CME Monograph)
Activity Description and Purpose
This educational activity is intended to help clinicians identify patients with thyroid eye disease (TED) who require intervention for elevated blood glucose levels prior to treatment for TED with the insulin-like growth factor 1 receptor antagonist teprotumumab. Clinicians will also learn to apply evidence to manage patients who require intervention for glycemic control during treatment for TED with teprotumumab. The desired results of this activity are for eye care professionals to use a multidisciplinary approach to increase their ability to identify and manage hyperglycemia in patients who require treatment of TED.
This educational activity is intended for ophthalmologists, oculoplastic surgeons, and neuro-ophthalmologists.
After completing this activity, participants will be better able to:
- Identify patients with thyroid eye disease who require intervention for elevated blood glucose prior to treatment
- Apply evidence to manage patients who require intervention for glycemic control during treatment of thyroid eye disease
Andrea Kossler, MD, FACS (Chair)
Sonalika Khachikian, MD
Lilly Wagner, MD
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Sonalika Khachikian, MD, is a consultant for Amgen Inc; is on the speakers bureau for Amgen Inc; and is on the advisory board of Novo Nordisk A/S*.
Andrea Kossler, MD, is a consultant for Acelyrin, Inc, Amgen Inc, Argenx, Genentech, Inc, and Immunovant, Inc; is an advisory board member of Arrowhead Pharmaceuticals; and is a contracted researcher for Amgen Inc, Kriya Therapeutics, Lassen Therapeutics, Sling Therapeutics, and Viridian Therapeutics, Inc.
Lilly Wagner, MD, has no relevant commercial relationships to disclose.
Hadi Kaakour, MD, was formerly an advisory board member of Alimera Sciences*.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
* The financial relationship existed during the past 24 months but has now ended
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Amgen Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Amgen Inc.
This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. 309
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation